A Rebuke To Pharma Globalization? Coronavirus Shows Value Of Regional Supply Chain Redundancy
As virus impedes China’s API production and spreads to other global manufacturing centers, need for robust supply chain alternatives becomes clear.
You may also be interested in...
As the coronavirus spreads beyond China, biopharma companies are taking precautions, with some more wary than others.
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Indian pharmaceutical companies will soon be asked to seek a no objection certificate for the export of 12 APIs and their formulations, as the country deals with Chinese raw material supply disruptions on the back of the coronavirus crisis. However, the move is not expected to impact the export quantum for now.